Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Lipigon Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 1/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Stefan Nilsson

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	8.8yrs
CEO sahipliği	1.5%
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	3.1yrs

Son yönetim güncellemeleri

Recent updates

CEO

Stefan Nilsson (45 yo)

8.8yrs

Görev süresi

Dr. Stefan K. Nilsson serves as the Chief Executive Officer of Lipigon Pharmaceuticals AB since 2016. Dr. Nilsson is an entrepreneur and Co-Founder of Lipigon. Dr. Nilsson has been central in all Lipigon’s...

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Lars Öhman	Business Development Manager & Chairman	12.8yrs	Veri yok	0.23% SEK 87.3k
Fredrik Lindgren	Director	less than a year	Veri yok	Veri yok
Jessica Martinsson	Independent Director	3.4yrs	Veri yok	0.11% SEK 42.0k
David Westberg	Independent Director	1.8yrs	Veri yok	0.020% SEK 7.6k
Johannes Hulthe	Director	3.8yrs	Veri yok	0.13% SEK 50.9k
Maj Hedtjarn	Scientific Advisor	no data	Veri yok	Veri yok
Ludger Scheja	Scientific Advisor	no data	Veri yok	Veri yok
Sander Kersten	Scientific Advisor	no data	Veri yok	Veri yok
Troels Koch	Scientific Advisor	no data	Veri yok	Veri yok
Jorg Heeren	Scientific Advisor	no data	Veri yok	Veri yok
Eva Lindqvist	Independent Director	2.8yrs	Veri yok	0.61% SEK 229.0k

3.1yrs

Ortalama Görev Süresi

57.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: LPGO 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.1 yıldır).

Lipigon Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Co-Founder & CEO recently bought kr75k worth of stock

Co-Founder & CEO recently bought kr75k worth of stock

Co-Founder & CEO recently bought kr101k worth of stock

Co-Founder & CEO recently bought kr135k worth of stock

Business Development Manager & Chairman exercised options to buy kr146k worth of stock.

Co-Founder & CEO recently bought kr68k worth of stock

Recent updates

Co-Founder & CEO recently bought kr75k worth of stock

Co-Founder & CEO recently bought kr75k worth of stock

Forecast to breakeven in 2026

New major risk - Financial position

Co-Founder & CEO recently bought kr101k worth of stock

The Swedish Medical Products Agency Approves Lipigon's Phase II Study with Lipisense

Co-Founder & CEO recently bought kr135k worth of stock

Business Development Manager & Chairman exercised options to buy kr146k worth of stock.

Lipigon Pharmaceuticals AB (Publ) Announces Lipisense Progressing to Phase II Trials

Lipigon Pharmaceuticals AB (Publ) Reports A Statically Confirms reduction of target protein ANGPTL4 after repeate treatment with Lipisense ®

Lipigon Applies for Clinical Trial Phase II for Lipisense

New major risk - Revenue and earnings growth

Co-Founder & CEO recently bought kr68k worth of stock

Lipigon Pharmaceuticals AB (publ) Announces Positive Safety Results and Encouraging Target Engagement Data from the Phase I Lipisense Trial

Lipigon Announces Further Positive Data from Phase I Trial of Lipisense

Third quarter 2022 earnings released: kr0.36 loss per share (vs kr1.18 loss in 3Q 2021)

Less than half of directors are independent

Lipigon Pharmaceuticals AB (publ) Announces Positive Top-Line Data from Phase I Clinical Study of Lipisense

Lipigon Pharmaceuticals AB (Publ) Announces Liver-Specific Treatment of Target Protein ANGPTL4 Is Effective and Safe

Lipigon Pharmaceuticals AB Announces First-In-Human Phase I Trial with Lipigon's Lipid-Lowering Candidate Lipisense

Lipigon Receives CTA Approval for Lipid-Lowering Candidate Lipisense

No independent directors

Lipigon Pharmaceuticals AB Confirms Patent Application for Drug Candidate Lipisense in US

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Lipigon Pharmaceuticals AB (publ) Ready to Apply for Clinical Trials After Successful Completion of Preclinical Safety Studies

Lipigon Pharmaceuticals AB (Publ) Completes Another Preclinical Study with Drug Candidate Lipisense

Lipigon Announces Positive Results from Preclinical Study for Lipid-Lowering Drug Candidate Lipisense

Third quarter 2021 earnings: Revenues in line with analyst expectations

Lipigon Expands Collaboration with Hitgen by Selecting Second Target

CEO

Görev süresi

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş